FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004208083> ?p ?o ?g. }

• W2004208083 endingPage "86" @default.
• W2004208083 startingPage "75" @default.
• W2004208083 abstract "The aim of this work is to evaluate the anti-thromboxane activity of two pure enantiomers of (R,S)-BM-591, a nitrobenzene sulfonylurea chemically related to torasemide, a loop diuretic. The drug affinity for thromboxane A2 receptor (TP) of human washed platelets has been determined. In these experiments, (R)-BM-591 (IC50 = 2.4+/-0.1 nM) exhibited a significant higher affinity than (S)-BM-591 (IC50 = 4.2+/-0.15 nM) for human washed platelets TP receptors. Both enantiomers were stronger ligands than SQ-29548 (IC50 = 21.0+/-1.0 nM) and sulotroban (IC50 = 930+/-42 nM), two reference TXA2 receptor antagonists. Pharmacological characterisations of (S)-BM-591 and (R)-BM-591 were compared in several models. Thus, (R)-BM-591 strongly prevented platelet aggregation induced by arachidonic acid (AA) (600 microM) and U-46619 (1 microM) while (S)-BM-591 showed a lower activity. On isolated tissues pre-contracted by U-46619, a stable TXA2 agonist, (S)-BM-591 was more potent in relaxing guinea-pig trachea (EC50 = 0.272+/-0.054 microM) and rat aorta (EC50 = 0.190+/-0.002 microM) than (R)-BM-591 (EC50 of 9.60+/-0.63 microM and 0.390+/-0.052 microM, respectively). Moreover, at 1 microM, (R)-BM-591 totally inhibited TXA2 synthase activity, expressed as TXB2 production from human platelets, while at the same concentration, (S)-BM-591 poorly reduced the TXB2 synthesis (22%). Finally, in rats, both enantiomers lost the diuretic activity of torasemide. In conclusion, (R)-BM-591 exhibits a higher affinity and antagonism on human platelet TP receptors than (S)-BM-591 as well as a better thromboxane synthase inhibitory potency. In contrast, (S)-BM-591 is more active than the (R)-enantiomer in relaxing smooth muscle contraction of rat aorta and trachea guinea pig. Consequently, (R)-BM-591 represents the best candidate for further development in the field of thrombosis disorders." @default.
• W2004208083 created "2016-06-24" @default.
• W2004208083 creator A5020685154 @default.
• W2004208083 creator A5023678796 @default.
• W2004208083 creator A5041424887 @default.
• W2004208083 creator A5081430054 @default.
• W2004208083 creator A5082090154 @default.
• W2004208083 date "2004-10-01" @default.
• W2004208083 modified "2023-09-27" @default.
• W2004208083 title "Pharmacological evaluation of both enantiomers of (R,S)-BM-591 as thromboxane A2 receptor antagonists and thromboxane synthase inhibitors" @default.
• W2004208083 cites W103769008 @default.
• W2004208083 cites W1530739311 @default.
• W2004208083 cites W1572362848 @default.
• W2004208083 cites W1908056863 @default.
• W2004208083 cites W1975965387 @default.
• W2004208083 cites W1980727193 @default.
• W2004208083 cites W1981985421 @default.
• W2004208083 cites W1983599594 @default.
• W2004208083 cites W2005725339 @default.
• W2004208083 cites W2006840712 @default.
• W2004208083 cites W2011508883 @default.
• W2004208083 cites W2019107385 @default.
• W2004208083 cites W2019171004 @default.
• W2004208083 cites W2026652904 @default.
• W2004208083 cites W2030087792 @default.
• W2004208083 cites W2035657173 @default.
• W2004208083 cites W2043711735 @default.
• W2004208083 cites W2048264802 @default.
• W2004208083 cites W2053062678 @default.
• W2004208083 cites W2053481310 @default.
• W2004208083 cites W2056574594 @default.
• W2004208083 cites W2074337679 @default.
• W2004208083 cites W2078328099 @default.
• W2004208083 cites W2079362203 @default.
• W2004208083 cites W2079472798 @default.
• W2004208083 cites W2081402100 @default.
• W2004208083 cites W2091788512 @default.
• W2004208083 cites W2092397822 @default.
• W2004208083 cites W2114632037 @default.
• W2004208083 cites W2127631847 @default.
• W2004208083 cites W2129965007 @default.
• W2004208083 cites W2130483535 @default.
• W2004208083 cites W2146972322 @default.
• W2004208083 cites W2152396641 @default.
• W2004208083 cites W2157724147 @default.
• W2004208083 cites W2169875869 @default.
• W2004208083 doi "https://doi.org/10.1016/j.prostaglandins.2004.07.007" @default.
• W2004208083 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15560117" @default.
• W2004208083 hasPublicationYear "2004" @default.
• W2004208083 type Work @default.
• W2004208083 sameAs 2004208083 @default.
• W2004208083 citedByCount "1" @default.
• W2004208083 countsByYear W20042080832018 @default.
• W2004208083 crossrefType "journal-article" @default.
• W2004208083 hasAuthorship W2004208083A5020685154 @default.
• W2004208083 hasAuthorship W2004208083A5023678796 @default.
• W2004208083 hasAuthorship W2004208083A5041424887 @default.
• W2004208083 hasAuthorship W2004208083A5081430054 @default.
• W2004208083 hasAuthorship W2004208083A5082090154 @default.
• W2004208083 hasConcept C126322002 @default.
• W2004208083 hasConcept C170493617 @default.
• W2004208083 hasConcept C173202427 @default.
• W2004208083 hasConcept C181199279 @default.
• W2004208083 hasConcept C185592680 @default.
• W2004208083 hasConcept C202751555 @default.
• W2004208083 hasConcept C2776785769 @default.
• W2004208083 hasConcept C2777752497 @default.
• W2004208083 hasConcept C2778078955 @default.
• W2004208083 hasConcept C2778938600 @default.
• W2004208083 hasConcept C2780978440 @default.
• W2004208083 hasConcept C2781024287 @default.
• W2004208083 hasConcept C486523 @default.
• W2004208083 hasConcept C51603380 @default.
• W2004208083 hasConcept C55493867 @default.
• W2004208083 hasConcept C71240020 @default.
• W2004208083 hasConcept C71924100 @default.
• W2004208083 hasConcept C86803240 @default.
• W2004208083 hasConcept C89560881 @default.
• W2004208083 hasConcept C98274493 @default.
• W2004208083 hasConceptScore W2004208083C126322002 @default.
• W2004208083 hasConceptScore W2004208083C170493617 @default.
• W2004208083 hasConceptScore W2004208083C173202427 @default.
• W2004208083 hasConceptScore W2004208083C181199279 @default.
• W2004208083 hasConceptScore W2004208083C185592680 @default.
• W2004208083 hasConceptScore W2004208083C202751555 @default.
• W2004208083 hasConceptScore W2004208083C2776785769 @default.
• W2004208083 hasConceptScore W2004208083C2777752497 @default.
• W2004208083 hasConceptScore W2004208083C2778078955 @default.
• W2004208083 hasConceptScore W2004208083C2778938600 @default.
• W2004208083 hasConceptScore W2004208083C2780978440 @default.
• W2004208083 hasConceptScore W2004208083C2781024287 @default.
• W2004208083 hasConceptScore W2004208083C486523 @default.
• W2004208083 hasConceptScore W2004208083C51603380 @default.
• W2004208083 hasConceptScore W2004208083C55493867 @default.
• W2004208083 hasConceptScore W2004208083C71240020 @default.
• W2004208083 hasConceptScore W2004208083C71924100 @default.
• W2004208083 hasConceptScore W2004208083C86803240 @default.
• W2004208083 hasConceptScore W2004208083C89560881 @default.

• next